Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex
Yu‐Yi Chu(The University of Texas MD Anderson Cancer Center), Mien‐Chie Hung(Precision Therapeutics (United States))
Cited by 37
Related Papers
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
|Nature Communications|2016|1.1k
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
|Nature Communications|2018|427
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
|Journal of Clinical Investigation|2019|380
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
|Journal of Clinical Investigation|2021|311